Clinical Trial Update: An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rimonabant for nonalcoholic steatohepatitis in patients with type 2 diabetes was terminated; no final efficacy results were reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Fatty Liver | Phase 3 | Status: TERMINATED